AVT-12 Weight Loss Study Abstract

March 4, 2010 - PRLog -- One-year Findings from Controlled Trial of AVT-12 Combination Drug Product on Weight Loss and Various Metabolic Risk Factors

A. Nielsen, P. Anderson, S. Das

Effective weight loss interventions ideally result not only in the promotion of weight loss, but also contribute to favorable changes in metabolic risk factors for chronic disease in overweight and obese subjects. The weight loss combination drug product, AVT-12 is thought to improve GPR39 affinity of the hormone, obestatin.  Use of combination drug products including agents targeted at distinct regulatory pathways may produce significant additive or synergistic effects on weight loss. The purpose of this study is to test the efficacy of AVT-12 in overweight and obese individuals as compared to a placebo control group at 12 months. In addition to bodyweight, measures include biochemical factors (total cholesterol, high density lipoprotein, low density lipoprotein, triglycerides, glucose, insulin, leptin and C-reactive protein. At point of randomization, participants (n=451) were 47(11) (mean [SD]) years of age, with BMI 36.0(3.7) kg/m2, weight 98.1(10.4) kg. One-year data are available for 94% of study participants (n=424) and weight loss is -27.7(6.7), -3.2(2.8) kg for the treatment group and control group, respectively, a weight loss of -39.3% and -3.4%, respectively. CRP decreased significantly in the treatment group, from 9.3% in the lowest risk category (CRP less than 1 ng/mL) at baseline, to 44.7% at 12 months, but was essentially unchanged in the control group. Findings from this study suggest that AVT-12 is an effective weight loss combination drug product and may produce significant favorable changes in risk factors for chronic disease.



Contact:
Paul Roth
Asst. Public Affairs Director
ITCES Corporation
(213) 283-6570
http://AVT12.info

# # #

ITCES Corporation partners with innovators to evaluate and develop applied biotherapeutics from concept to market. ITCES delivers timely value to clients by facilitating and analyzing critical research, while protecting intellectual property.